Immuneering
IMRX
52 hedge funds and large institutions have $130M invested in Immuneering in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 4 closing their positions.
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
6% more funds holding
Funds holding: 49 → 52 (+3)
1.15% less ownership
Funds ownership: 59.04% → 57.9% (-1.1%)
26% less capital invested
Capital invested by funds: $176M → $130M (-$45.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$1.31M |
| 2 |
BlackRock
New York
|
+$812K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$408K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$393K |
| 5 |
State Street
Boston,
Massachusetts
|
+$254K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$436K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$425K |
| 4 |
TAM
Tucker Asset Management
Littleton,
Colorado
|
-$112K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$63.6K |
IMRX Hedge Fund Activity: Q3 2023 in Review
52 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q3 2023, worth a combined $130M — down 26% from $176M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IMRX positions and 4 closed out — a net gain of 3 holders — while 24 added to existing stakes and 11 trimmed.
The largest buyer was TD Asset Management, adding an estimated $1.31M. The largest seller was Bank of Montreal, exiting entirely with an estimated $8M sold.
- 52 institutional investors held Immuneering (IMRX) as of Q3 2023, up from 49 in Q2 2023.
- Funds reported $130M of Immuneering stock for Q3 2023, down 26% quarter-over-quarter.
- 7 funds opened new Immuneering positions in Q3 2023 and 4 closed out, a net change of +3 holders.
- The largest Immuneering buyer in Q3 2023 was TD Asset Management, an estimated $1.31M added.
- The largest Immuneering seller in Q3 2023 was Bank of Montreal, an estimated $8M sold.
Based on aggregated 13F filings for Q3 2023.